Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4
- PMID: 24759783
- PMCID: PMC4025922
- DOI: 10.1038/ncomms4729
Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4
Abstract
Mounting evidence indicates that oncogenic Ras can modulate cell autonomous inflammatory cytokine production, although the underlying mechanism remains unclear. Here we show that squamous cell carcinoma antigens 1 and 2 (SCCA1/2), members of the Serpin family of serine/cysteine protease inhibitors, are transcriptionally upregulated by oncogenic Ras via MAPK and the ETS family transcription factor PEA3. Increased SCCA expression leads to inhibition of protein turnover, unfolded protein response, activation of NF-κB and is essential for Ras-mediated cytokine production and tumour growth. Analysis of human colorectal and pancreatic tumour samples reveals a positive correlation between Ras mutation, enhanced SCCA expression and IL-6 expression. These results indicate that SCCA is a Ras-responsive factor that plays an important role in Ras-associated cytokine production and tumorigenesis.
Figures








Similar articles
-
Role of SERPINB3 in hepatocellular carcinoma.Ann Hepatol. 2014 Nov-Dec;13(6):722-7. Ann Hepatol. 2014. PMID: 25332258 Review.
-
Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells.Int J Cancer. 2000 Jul 20;89(4):368-77. doi: 10.1002/1097-0215(20000720)89:4<368::aid-ijc9>3.0.co;2-6. Int J Cancer. 2000. PMID: 10956412
-
Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.Oncol Rep. 2019 Feb;41(2):1253-1263. doi: 10.3892/or.2018.6895. Epub 2018 Nov 28. Oncol Rep. 2019. PMID: 30535496
-
Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.Br J Cancer. 2018 Jan;118(1):72-78. doi: 10.1038/bjc.2017.390. Epub 2017 Nov 7. Br J Cancer. 2018. PMID: 29112685 Free PMC article.
-
SERPINB3, apoptosis and autoimmunity.Autoimmun Rev. 2009 Dec;9(2):108-12. doi: 10.1016/j.autrev.2009.03.011. Epub 2009 Mar 27. Autoimmun Rev. 2009. PMID: 19332150 Review.
Cited by
-
A role for IL-34 in osteolytic disease of multiple myeloma.Blood Adv. 2019 Feb 26;3(4):541-551. doi: 10.1182/bloodadvances.2018020008. Blood Adv. 2019. PMID: 30782613 Free PMC article.
-
SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.J Clin Invest. 2023 Aug 1;133(15):e163841. doi: 10.1172/JCI163841. J Clin Invest. 2023. PMID: 37279067 Free PMC article.
-
The Effect of Heparin and Other Exogenous Glycosaminoglycans (GAGs) in Reducing IL-1β-Induced Pro-Inflammatory Cytokine IL-8 and IL-6 mRNA Expression and the Potential Role for Reducing Inflammation.Pharmaceuticals (Basel). 2024 Mar 14;17(3):371. doi: 10.3390/ph17030371. Pharmaceuticals (Basel). 2024. PMID: 38543157 Free PMC article.
-
Liver pro-oncogenic potential of SERPINB3.Oncoscience. 2014 Sep 3;1(8):502-3. doi: 10.18632/oncoscience.76. eCollection 2014. Oncoscience. 2014. PMID: 25594056 Free PMC article. No abstract available.
-
SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer.Oncotarget. 2017 Feb 28;8(9):15732-15743. doi: 10.18632/oncotarget.14997. Oncotarget. 2017. PMID: 28178650 Free PMC article.
References
-
- Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689. - PubMed
-
- Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22. - PubMed
-
- Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6:447–458. - PubMed
-
- Kuilman T, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019–1031. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50CA095103/CA/NCI NIH HHS/United States
- P50 CA095103/CA/NCI NIH HHS/United States
- R01GM97355/GM/NIGMS NIH HHS/United States
- R01CA100126/CA/NCI NIH HHS/United States
- R01 GM097355/GM/NIGMS NIH HHS/United States
- U01CA168409/CA/NCI NIH HHS/United States
- R01CA159222/CA/NCI NIH HHS/United States
- T32 CA009176/CA/NCI NIH HHS/United States
- R01CA129536/CA/NCI NIH HHS/United States
- R01 CA129536/CA/NCI NIH HHS/United States
- R01 CA159222/CA/NCI NIH HHS/United States
- R01 CA100126/CA/NCI NIH HHS/United States
- U01 CA168409/CA/NCI NIH HHS/United States
- T32CA009176/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials